-
公开(公告)号：US20080262284A1
公开(公告)日：2008-10-23
申请号：US12163568
申请日：2008-06-27
申请人： Geraldine Marcenyac , Mark Alfonso , Lane Gehrlein , Stephen Howard , Lino Tavares , Ronald Greenbaum , Seth Levy , Benjamin Oshlack
发明人： Geraldine Marcenyac , Mark Alfonso , Lane Gehrlein , Stephen Howard , Lino Tavares , Ronald Greenbaum , Seth Levy , Benjamin Oshlack
CPC分类号： A61K9/7038 , A61B50/36 , A61B2050/002 , A61F13/00063 , A61F13/023 , A61F13/0253 , A61F13/0259 , A61F2013/00859 , A61K9/7023 , A61K31/4468 , A62D3/30 , B09B3/0075 , B09B2220/14 , Y10T428/1334 , Y10T428/2817
摘要： The present invention relates to a disposable article to prevent the misuse of a transdermal dosage form (FIG. 1(a)). The article is comprised of an outer layer (1) having an inner layer-facing side and an opposite side; an inner layer (3) having an outer layer-facing side and an opposite side, the inner layer (3) joined to the outer layer (1) to form one or more closed material reservoir (2) between the outer layer-facing side of the inner layer (2) and the inner layer-facing side of the outer layer (1); and adhesive (4) covering a first portion of the opposite side of the inner layer (3), wherein the adhesive (4) is a heat activated adhesive that changes color and/or is activated when the article is subjected to elevated temperatures, thereby sealing the transdermal dosage form within the article.
摘要翻译： 本发明涉及一种用于防止误用经皮剂型的一次性制品（图1（a））。 该制品由具有内层侧和相对侧的外层（1）组成; 具有外层相对侧和相对侧的内层（3），所述内层（3）接合到所述外层（1），以在所述外层相对侧之间形成一个或多个封闭材料容器（2） 的内层（2）和外层（1）的内层面侧。 以及覆盖所述内层（3）的相对侧的第一部分的粘合剂（4），其中所述粘合剂（4）是当所述制品经受高温时改变颜色和/或活化的热活化粘合剂，由此 将透皮剂型密封在制品内。
-
公开(公告)号：US08496960B2
公开(公告)日：2013-07-30
申请号：US10493002
申请日：2002-10-23
IPC分类号： A61F13/00
CPC分类号： A61K31/138 , A61K9/7023 , A61K31/517
摘要： A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
摘要翻译： 通过经皮制剂施用无定形的特拉唑嗪，可以有效治疗人类前列腺增生症的方法。 优选地，将透皮制剂施用于患者的皮肤并保持与皮肤接触至少约24小时，优选约3至约8天。
-
公开(公告)号：US20050031678A1
公开(公告)日：2005-02-10
申请号：US10945222
申请日：2004-09-20
申请人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
发明人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
IPC分类号： A61K9/70 , A61K31/517
CPC分类号： A61K9/7069
摘要： A method of effectively treating benign prostatic hypertension in humans is achieved by administering terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
摘要翻译： 通过经皮制剂施用特拉唑嗪可以有效治疗人类前列腺增生症的方法。 优选地，将透皮制剂施用于患者的皮肤并保持与皮肤接触至少约24小时，优选约3至约8天。
-
公开(公告)号：US20050064022A1
公开(公告)日：2005-03-24
申请号：US10493002
申请日：2002-10-23
申请人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
发明人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
IPC分类号： A61K9/70 , A61K31/138 , A61K31/517
CPC分类号： A61K31/138 , A61K9/7023 , A61K31/517
摘要： A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
摘要翻译： 通过经皮制剂施用无定形的特拉唑嗪，可以有效治疗人类前列腺增生症的方法。 优选地，将透皮制剂施用于患者的皮肤并保持与皮肤接触至少约24小时，优选约3至约8天。
-
公开(公告)号：US09259397B2
公开(公告)日：2016-02-16
申请号：US10045607
申请日：2001-10-23
申请人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
发明人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
CPC分类号： A61K9/7053 , A61K9/0014 , A61K9/7061 , A61K9/7069 , A61K31/445 , A61K31/55 , A61K47/10 , A61K47/38
摘要： A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.
-
公开(公告)号：US07018649B2
公开(公告)日：2006-03-28
申请号：US10045595
申请日：2001-10-23
申请人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
发明人： Lino Tavares , Ihor Shevchuk , Mark Alfonso , Geraldine Marcenyac , Kirti Valia
CPC分类号： A61K9/7061 , A61K9/7069 , A61K31/4422
摘要： A method of effectively treating hypertension in humans is achieved by administering felodipine via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours days, and preferably for about 3 to about 8 days.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.039 秒)
